this moves possible CE sales MAINLY to 4th qtr & laterRegulatory Update Europe
Subsequent to the end of the second financial quarter of FY2022, the Company received the CE mark for its REVEALCOVID19® PLUS Total Antibody Test and commenced its commercialization efforts in all markets accepting the CE mark. Sales generated from this product will contribute towards the Company’s overall sales within the coming months